Hematological NeoplasmsPhase 1NCT02223052
Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies
A Phase 1 study testing CC-486 and Vidaza in people with Hematological Neoplasms and Non-Hodgkin's Lymphoma, run by Celgene at 10 sites in United States.
Trial summary
This is a Phase 1, open-label, multicenter, randomized, 2-stage crossover study consisting of 2 phases: Stage I - Pharmacokinetics (Bioequivalence), with an Extension Stage II - Pharmacokinetics (Food Effect) with an Extension This study will enroll approximately 60 subjects in stage I and 60 subjects in stage II with… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Hematological Neoplasms, Non-Hodgkin's Lymphoma, Hodgkin's Lymphoma
- What is being tested?
- CC-486 and Vidaza
- Type of treatment
- Pill or oral medicine, Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 89 participants
- Where
- 10 sitesUnited States
- Study dates
- 27 Oct 2014to 18 Dec 2018
- Phase
- Phase 1
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Subjects must satisfy the following criteria to be enrolled in the study:
- Age ≥ 18 years of age at the time of signing the informed consent document.
- Understand and voluntarily sign an informed consent document prior to any study related assessments/procedures are conducted.
- Documented diagnosis of any of the following:
- Myelodysplastic Syndrome (MDS) according to the World Health Organization (WHO) 2008 classification
- Acute myeloid leukemia (AML)
Show all 33Show fewer
- Multiple myeloma (MM), limited to those patients for whom standard curative or palliative treatments do not exist or are no longer effective
- Non-Hodgkin's lymphoma (NHL), limited to those patients for whom standard curative or palliative treatment do not exist or are no longer effective,
- Hodgkin's lymphoma (HL), limited to those patients for whom standard curative or palliative treatment do not exist or are no longer effective
- Metastatic or inoperable solid tumors* (except gastrointestinal tumors or tumors that originated or metastasized to the liver) for which no standard treatment exists, or have progressed or recurred following prior therapy.
- Subjects must not be eligible for therapy of higher curative potential where an alternative treatment has been shown to prolong survival in an analogous population.
- Patients with a history of treated brain metastases should be clinically stable for ≥ 4 weeks prior to signing the informed consent. Glucocorticoid therapy for central nervous system (CNS) edema is permitted if ≤ 20 mg of prednisolone (or equivalent).
- Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.
- Have a life expectancy of ≥ 3 months.
- Have stable renal function without dialysis for at least 2 months prior to Investigational Product (IP) administration defined by:
- Serum creatinine < 2.5 x the upper limit of normal (ULN)
- An average calculated creatinine clearance > 30 mL/min/1.73 m^2
- Have organ and marrow function at the screening and pre-dose visits as defined by:
- Hemoglobin ≥ 8 g/dL
- Absolute neutrophil count (ANC) ≥ 0.75 x 10^3/uL without treatment with a myeloid growth factor within 3 days prior to first dose of IP
- Platelets ≥ 30 x 10^3/uL
- Total bilirubin ≤ 1.5 x Upper Limits of Normal (ULN)
- Aspartate aminotransferase (AST) ≤ 2 x ULN
- Alanine aminotransferase (ALT) ≤ 2 x ULN
- Have a 12-lead Electrocardiogram (ECG) that is not clinically significant at screening, as determined by the investigator
- Females of childbearing potential (FCBP) may participate, providing the subject meets the following conditions:
- Agree to use at least two effective contraceptive methods (oral, injectable, or implantable hormonal contraceptive; tubal ligation; intra-uterine device; barrier contraceptive with spermicide; or vasectomized partner) or agree to practice true abstinence throughout the study, and for 3 months following the last dose of IP; and
- Negative serum pregnancy test at screening (sensitivity of at least 25 mIU/mL); (Note that the screening serum pregnancy test can be used as the test prior to starting IP in the pharmacokinetics phase if it is performed within the 72-hour timeframe), and
- Negative serum or urine pregnancy test (investigator's discretion; sensitivity of at least 25 mIU/mL) within 72 hours prior to starting IP in the extension phase. (Note: subjects must have negative serum or urine pregnancy test prior to dosing on Day 1 of each treatment cycle in the extension phase.)
- Male subjects must:
- Practice true abstinence* or agree to the use of at least two physician-approved contraceptive methods throughout the course of the study and should avoid fathering a child during the course of the study for at least 3 months following the last dose of IP.
- True abstinence is acceptable when this is in line with the preferred and usual lifestyle of the patient. [Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception].
- Able to adhere to the study visit schedule and other protocol requirements.
Who cannot join
- Women who are pregnant or nursing (lactating).
- Gastrointestinal tumors, tumors that have originated or metastasized to the liver, or other tumors known to interfere with the absorption, distribution, metabolism, or excretion of drugs.
- Had chemotherapy or radiotherapy within 4 weeks prior to the first day of Investigational Product (IP) administration.
- Have been treated with an investigational agent within 4 weeks prior to the first day of IP administration.
- Have ongoing clinically significant adverse event(s) due to prior treatments administered as determined by the investigator.
- Significant active cardiac disease within the previous 6 months, including:
Show all 17Show fewer
- New York Heart Association (NYHA) class IV congestive heart failure
- Significant cardiac arrhythmia or unstable angina or angina requiring surgical or medical intervention; and/or
- Myocardial infarction
- Have known or suspected hypersensitivity to azacitidine or any other ingredient used in the manufacturing of Azacitidine.
- Uncontrolled systemic fungal, bacterial, or viral infection (defined as ongoing signs/symptoms related to the infection without improvement despite appropriate antibiotics, antiviral therapy, and/or other treatment)
- History of inflammatory bowel disease (e.g. Crohn's disease, ulcerative colitis), celiac disease, prior gastrectomy, gastric bypass, upper bowel removal, or any other gastrointestinal disorder or defect that would interfere with the absorption of the study drug and/or predispose the subject to an increased risk of gastrointestinal toxicity.
- Any significant medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from participating in the study.
- Any condition including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study
- Any condition that confounds the ability to interpret data from the study
- Impaired ability to swallow oral medication
- Any condition that confounds the ability to interpret data from the study
Trial locations and contacts
10 sites in 1 country.
10 sites in 1 country
United States10 sites
Cleveland Clinic Foundation
Cleveland, Ohio, 44195
Henry Ford Health System
Detroit, Michigan, 48202-268
Greenville Hospital System
Greenville, South Carolina, 29605
The Methodist Hospital Research Institute l
Houston, Texas, 77030
University of Iowa
Iowa City, Iowa, 52242
Vanderbilt- Ingram Cancer Center
Nashville, Tennessee, 37232-6307
Cancer Institute of New Jersey
New Brunswick, New Jersey, 08903
Scottsdale Healthcare Research Institute
Scottsdale, Arizona, 85258
Mayo Clinic - Arizona
Scottsdale, Arizona, 85259
University of Arizona Cancer Center
Tucson, Arizona, 85724
About this study
Official title: A Phase 1, Open-label, Multicenter, Randomized, 2-Period, Crossover Study to Evaluate the Bioequivalence and Food Effect Bioavailability of CC-486 (Oral Azacitidine) Tablets in Adult Cancer Subjects
This is a Phase 1, open-label, multicenter, randomized, 2-stage crossover study consisting of 2 phases:
Stage I - Pharmacokinetics (Bioequivalence), with an Extension Stage II - Pharmacokinetics (Food Effect) with an Extension
This study will enroll approximately 60 subjects in stage I and 60 subjects in stage II with hematologic or solid tumor malignancies, excluding gastrointestinal tumors and tumors that have originated or metastasized to the liver for which no standard treatment exists or have progressed or recurred following prior therapy. Subjects must not be eligible for therapy of higher curative potential where an alternative treatment has been shown to prolong survival in an analogous population. Approximately 23 sites in the US and 2 in Canada will participate in this study.
Read the detailed description
Stage I - Pharmacokinetics (Bioequivalence)
Subjects will be randomized to receive CC-486 300 mg orally on each of the two pharmacokinetic (PK) study days based on the dosing sequences they are randomized to:
Dosing Sequence 1: 2x150 mg tablets followed by 1x30 mg tablet. Dosing Sequence 2: 1x300 mg tablet followed by 2x150 mg tablets. Each dose will be administered in the clinic at least 48 hours apart between PK dosing day 1 and PK dosing day 2 over a period no longer than 10 days under fasted conditions.
Stage II - Pharmacokinetics (Food Effect)
Subjects will be randomized to receive CC-486 300 mg orally on each of the two PK study days based on the dosing sequences they are randomized to:
Dosing Sequence 1: 1x300 mg tablet under fasted condition followed by 1x300 mg tablet under fed condition.
Dosing Sequence 2: 1x300 mg tablet under fed condition followed by 1x300 mg tablet under fasted condition.
Each dose will be administered in the clinic at least 48 hours apart between PK dosing day 1 and PK dosing day 2 over a period no longer than 10 days. The sponsor will generate the randomization scheme and assign subjects upon enrollment to the appropriate sequence for dosing:
Fasted condition: following an overnight fast of at least 10 hours, subjects will ingest oral Azacitidine with 240 mL of room temperature water. Subjects must fast for a minimum of 4 hours following oral Azacitidine administration. Subjects may drink water as desired, except for 1 hour before and 1 hour after oral Azacitidine administration.
Fed condition: following an overnight fast of at least 10 hours and following the performance of all required pre-dose assessments, subjects randomized to receive test medication in a fed state will begin ingesting a breakfast meal 30 (±5) minutes prior to the planned administration of oral Azacitidine. They will continue the entire meal within 20 to 25 minutes (no less than 20 minutes) from the time the meal is served. Subjects will then ingest oral Azacitidine with 240 mL of room temperature water. Subjects must fast a minimum of 4 hours following oral Azacitidine administration. Subjects may drink water as desired, except for 1 hour before and 1 hour after administration of oral Azacitidine.
Extension Phase (for subjects who have completed PK Stage I or Stage II) Subjects continuing beyond the pharmacokinetics phase (Stage I or Stage II) will enter the extension phase of the study at the discretion of the investigator to receive < 6 (four-week) cycles of Vidaza 75 mg/m2 IV or SC daily for 7 days in the clinic and repeat every 4 weeks per prescribed label at the discretion of the investigator for ≤ 6 (four-week) cycles.
- Conditions
- Hematological Neoplasms, Non-Hodgkin's Lymphoma, Hodgkin's Lymphoma, Lymphoma, Multiple Myeloma, Acute Myeloid Leukemia
- Being tested
- CC-486, Vidaza
- Keywords
- CC-486, Oral Azacitidine, Soli Tumor Malignancy, Hematological Malignancy, Leukemia, Lymphoma, Multiple Myeloma, Acute Myeloid Leukemia, Myelodysplastic Syndromes, Neoplasms, Melanoma, Breast Cancer, Metastatic Breast Cancer, Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Renal Cell Carcinoma, Glioblastoma Multiforme, Brain Cancer, Kidney Cancer, Lung cancer
- Medical subject headings
- Hematologic Neoplasms, Lymphoma, Non-Hodgkin, Hodgkin Disease, Lymphoma, Multiple Myeloma, Leukemia, Myeloid, Acute, Leukemia, Myelodysplastic Syndromes
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
CC-486Drug
Also called Oral Azacitdine
Arm 1: Two 150-mg tablets of CC-486 on Day 1 and 1 x 300 mg CC-486 on Day 2 Arm 2: 1 x 300mg tablet of CC 486 on Day 1 and 2 x 150mg CC-486 on Day 2
VidazaDrug
Also called Azacitidine for Injection, AZA
75mg/m^2 IV or SC daily x 7 days every 4 weeks for ≤ 6 (four-week) cycles
| Study group | Role | What they receive |
|---|---|---|
| CC-486 Arm 1 (Oral Azacitidine) Dosing Sequence 1 | Experimental | Two 150-mg tablets of CC-486 under fasting condition on PK dosing Day 1, followed by one 300-mg tablet of CC-486 on PK dosing Day 2; If PI chooses to treat the patient in the extension phase with Azacitidine, Vidaza (Azacitidine for Injection) 75 mg/m2 intravenously (IV) or subcutaneously (SC) daily x 7 days every 4 weeks for less than or equal to 6 (28-day) cycles will be administered. Receives: Drug: CC-486; Drug: Vidaza |
| CC-486 Arm 2 (Oral Azacitidine) Dosing Sequence 1 | Experimental | One 300-mg tablet of oral CC-486 under fasting condition on PK dosing Day 1, followed by one 300-mg tablet of oral CC-486 under fed condition on PK dosing Day 2; If PI chooses to treat the patient in the extension phase with Azacitidine, Vidaza (Azacitidine for Injection) 75 mg/m2 intravenously (IV) or subcutaneously (SC) daily x 7 days every 4 weeks for less than or equal to 6 (28-day) cycles will be administered. Receives: Drug: CC-486; Drug: Vidaza |
| CC-486 Arm 1 (Oral Azacitidine) Dosing Sequence 2 | Experimental | One 300-mg tablets of CC-486 under fasting condition on PK dosing Day 1, followed by two 150-mg tablets on PK dosing Day 2; If PI chooses to treat the patient in the extension phase with Azacitidine, Vidaza (Azacitidine for Injection) 75 mg/m2 intravenously (IV) or subcutaneously (SC) daily x 7 days every 4 weeks for less than or equal to 6 (28-day) cycles will be administered. Receives: Drug: CC-486; Drug: Vidaza |
| CC-486 Arm 2 (Oral Azacitidine) Dosing Sequence 2 | Experimental | One 300-mg tablet of oral CC-486 under fed condition on PK dosing Day 1, followed by one tablet of 300-mg oral CC-486 under fasted conditions on PK dosing Day 2; if PI chooses to treat the patient in the extension phase with Azacitidine, Vidaza (Azacitidine of Injection) 75 mg/m2 intravenously (IV) or subcutaneously (SC) daily x 7 days every 4 weeks for less than or equal to 6 (28-day) cycles will be administered. Receives: Drug: CC-486; Drug: Vidaza |
What is being measured
The primary outcome is the main question the study is designed to answer.
Pharmacokinetics Cmax - Stage I (Bioequivalence)
The observed maximum concentration
Measured: Day 1 and PK Dosing Day 2 prior to each dose administration of IP (CC-486), known as pre-dose, and over the 8-hour period following each dose administration of IP (CC-486) at 0.25, 0.5, 1, 1.5, 2, 2.5,3, 3.5, 4, 6, and 8 hours post-dose
Pharmacokinetics Tmax - Stage I (Bioequivalence)
The observed time to first maximum concentration
Measured: Day 1 and PK Dosing Day 2 prior to each dose administration of IP (CC-486), known as pre-dose, and over the 8-hour period following each dose administration of IP (CC-486) at 0.25, 0.5, 1, 1.5, 2, 2.5,3, 3.5, 4, 6, and 8 hours post-dose
Pharmacokinetics AUC-t - Stage I (Bioequivalence)
Area under the concentration-time curve from time zero to the last quantifiable time point calculated by the linear trapezoidal rule
Measured: Day 1 and PK Dosing Day 2 prior to each dose administration of IP (CC-486), known as pre-dose, and over the 8-hour period following each dose administration of IP (CC-486) at 0.25, 0.5, 1, 1.5, 2, 2.5,3, 3.5, 4, 6, and 8 hours post-dose
Pharmacokinetics AUC-infinity - Stage I (Bioequivalence)
Area under the concentration time-curve from time zero to infinity, calculated by the linear trapezoidal rule and extrapolated to infinity. It will be calculated as AUC∞ = [AUCt + Ct/λz]. Ct is the last quantifiable concentration
Measured: Day 1 and PK Dosing Day 2 prior to each dose administration of IP (CC-486), known as pre-dose, and over the 8-hour period following each dose administration of IP (CC-486) at 0.25, 0.5, 1, 1.5, 2, 2.5,3, 3.5, 4, 6, and 8 hours post-dose
Pharmacokinetics λz (Terminal Rate) - Stage I (Bioequivalence)
Terminal phase rate constant, determined by linear regression of the terminal points of the log-linear concentration-time curve
Measured: Dosing Day 1 and PK Dosing Day 2 prior to each dose administration of IP (CC-486), known as pre-dose, and over the 8-hour period following each dose administration of IP (CC-486) at 0.3.5, 4, 6, and 8 hours post-dose
Pharmacokinetics Terminal Half-Life (t½) - Stage I (Bioequivalence)
Terminal phase half-life, calculated according to the following equation: t½ = 0.693/λz
Measured: Dosing Day 1 and PK Dosing Day 2 prior to each dose administration of IP (CC-486), known as pre-dose, and over the 8-hour period following each dose administration of IP (CC-486) at 0.25, 0.5, 1, 1.5, 2, 2.5,3, 3.5, 4, 6, and 8 hours post-dose
Pharmacokinetics Apparent total clearance (CL/F) - Stage I (Bioequivalence)
Apparent total clearance, calculated as Dose/AUC∞
Measured: Day 1 and PK Dosing Day 2 prior to each dose administration of IP (CC-486), known as pre-dose, and over the 8-hour period following each dose administration of IP (CC-486) at 0.25, 0.5, 1, 1.5, 2, 2.5,3, 3.5, 4, 6, and 8 hours post-dose
Pharmacokinetics Apparent volume of distribution (Vd/F) - Stage I (Bioequivalence)
Apparent volume of distribution, calculated according to the equation: Vd/F = (CL/F) / λz
Measured: Day 1 and PK Dosing Day 2 prior to each dose administration of IP (CC-486), known as pre-dose, and over the 8-hour period following each dose administration of IP (CC-486) at 0.25, 0.5, 1, 1.5, 2, 2.5,3, 3.5, 4, 6, and 8 hours post-dose
Pharmacokinetics Cmax - Stage II (Food Effect Bioavailability)
The observed maximum concentration
Measured: PK Dosing Day 1 and PK Dosing Day 2 prior to each dose administration of IP (CC-486), known as pre-dose, and over the 8-hour period following each dose administration of IP (CC-486) at 0.25, 0.5, 1, 1.5, 2, 2.5,3, 3.5, 4, 6, and 8 hours post-dose.
Pharmacokinetics Tmax - Stage II (Food Effect Bioavailability)
The observed time to first maximum concentration
Measured: PK Dosing Day 1 and PK Dosing Day 2 prior to each dose administration of IP (CC-486), known as pre-dose, and over the 8-hour period following each dose administration of IP (CC-486) at 0.25, 0.5, 1, 1.5, 2, 2.5,3, 3.5, 4, 6, and 8 hours post-dose.
Pharmacokinetics AUC-t - Stage II (Food Effect Bioavailability)
Area under the concentration-time curve from time zero to the last quantifiable time point calculated by the linear trapezoidal rule.
Measured: PK Dosing Day 1 and PK Dosing Day 2 prior to each dose administration of IP (CC-486), known as pre-dose, and over the 8-hour period following each dose administration of IP (CC-486) at 0.25, 0.5, 1, 1.5, 2, 2.5,3, 3.5, 4, 6, and 8 hours post-dose.
Pharmacokinetics AUC-infinity - Stage II (Food Effect Bioavailability)
Area under the concentration time-curve from time zero to infinity, calculated by the linear trapezoidal rule and extrapolated to infinity. It will be calculated as AUC∞ = [AUCt + Ct/λz]. Ct is the last quantifiable concentration.
Measured: PK Dosing Day 1 and PK Dosing Day 2 prior to each dose administration of IP (CC-486), known as pre-dose, and over the 8-hour period following each dose administration of IP (CC-486) at 0.25, 0.5, 1, 1.5, 2, 2.5,3, 3.5, 4, 6, and 8 hours post-dose.
Pharmacokinetics λz (Terminal Rate) - Stage II (Food Effect Bioavailability)
Terminal phase rate constant, determined by linear regression of the terminal points of the log-linear concentration-time curve
Measured: PK Dosing Day 1 and PK Dosing Day 2 prior to each dose administration of IP (CC-486), known as pre-dose, and over the 8-hour period following each dose administration of IP (CC-486) at 0.25, 0.5, 1, 1.5, 2, 2.5,3, 3.5, 4, 6, and 8 hours post-dose.
Pharmacokinetics Terminal Half-Life (t½) - Stage II (Food Effect Bioavailability)
Terminal phase half-life, calculated according to the following equation: t½ = 0.693/λz
Measured: PK Dosing Day 1 and PK Dosing Day 2 prior to each dose administration of IP (CC-486), known as pre-dose, and over the 8-hour period following each dose administration of IP (CC-486) at 0.25, 0.5, 1, 1.5, 2, 2.5,3, 3.5, 4, 6, and 8 hours post-dose.
Pharmacokinetics Apparent total clearance (CL/F) - Stage II (Food Effect Bioavailability)
Apparent total clearance, calculated as Dose/AUC∞
Measured: PK Dosing Day 1 and PK Dosing Day 2 prior to each dose administration of IP (CC-486), known as pre-dose, and over the 8-hour period following each dose administration of IP (CC-486) at 0.25, 0.5, 1, 1.5, 2, 2.5,3, 3.5, 4, 6, and 8 hours post-dose.
Pharmacokinetics Apparent volume of distribution (Vd/F) - Stage II (Food Effect Bioavailability)
Apparent volume of distribution, calculated according to the equation: Vd/F = (CL/F) / λz
Measured: PK Dosing Day 1 and PK Dosing Day 2 prior to each dose administration of IP (CC-486), known as pre-dose, and over the 8-hour period following each dose administration of IP (CC-486) at 0.25, 0.5, 1, 1.5, 2, 2.5,3, 3.5, 4, 6, and 8 hours post-dose.
Secondary outcomes (1)
Adverse Events (AEs)
Adverse Event (AE) is defined as any noxious, unintended, or untoward medical occurrence that may appear or worsen in a subject during the course of a study. It may be a new intercurrent illness, a worsening concomitant illness, an injury, or any concomitant impairment of the subject's health, including laboratory test values regardless of etiology. Any worsening (i.e., any clinically significant adverse change in the frequency or intensity of a pre-existing condition) should be considered an AE.
Measured: Up to 18 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted22 Aug 2014 (estimated)
- Study start27 Oct 2014
- Primary completion11 Jun 2018
- Study completion18 Dec 2018
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Hematological NeoplasmsStudies of the same condition, open and under way.
- More trials run by CelgeneThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 89 participants (actual)
Sponsor and investigators
- Lead sponsor
- Celgene
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Du Lam, MD, Study director, Celgene
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02223052
- Sponsor's protocol ID
- CC-486-CAGEN-001
- Status last verified
- May 2020
- First submitted
- 20 Aug 2014
- Last updated
- 12 May 2020
- Results posted
- No
- Data monitoring committee
- No
- Expanded access
- Available